Evidence map›Paper›PMID 31273690›Full record

ReviewMethods in molecular biology (Clifton, N.J.)2019

Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development.

Arie Kaffman, Jordon D White, Lan Wei, Frances K Johnson, John H Krystal

Abstract readReview
In one paragraph

Review in Methods in molecular biology (Clifton, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Translational In Vivo Assays in Behavioral Biology.Annual review of pharmacology and toxicology · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Arie KaffmanDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. arie.kaffman@yale.edu.
Jordon D WhiteDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Lan WeiDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Frances K JohnsonDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
John H KrystalDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.

Funding

Microglia play a critical role in the long-term sequelae of early life stressR01MH100078 · NIMH · YALE UNIVERSITY · PI KAFFMAN, ARIE · 2014 to 2018
$2.2M
NIMH NIH HHS R01 MH100078
6 · The paper itself

Abstract

Most large pharmaceutical companies have downscaled or closed their clinical neuroscience research programs in response to the low clinical success rate for drugs that showed tremendous promise in animal experiments intended to model psychiatric pathophysiology. These failures have raised serious concerns about the role of preclinical research in the identification and evaluation of new pharmacotherapies for psychiatry. In the absence of a comprehensive understanding of the neurobiology of psychiatric disorders, the task of developing "animal models" seems elusive. The purpose of this review is to highlight emerging strategies to enhance the utility of preclinical research in the drug development process. We address this issue by reviewing how advances in neuroscience, coupled with new conceptual approaches, have recently revolutionized the way we can diagnose and treat common psychiatric conditions. We discuss the implications of these new tools for modeling psychiatric conditions in animals and advocate for the use of systematic reviews of preclinical work as a prerequisite for conducting psychiatric clinical trials. We believe that work in animals is essential for elucidating human psychopathology and that improving the predictive validity of animal models is necessary for developing more effective interventions for mental illness.

Indexed as

BiotechnologyDrug DevelopmentDrug Evaluation, PreclinicalTranslational Research, BiomedicalAnimal ExperimentationAnimalsBiomarkersCentral Nervous System AgentsClinical Trials as TopicHumansMental DisordersMolecular Targeted TherapyTreatment OutcomeBiomarkersCentral Nervous System AgentsAnimal modelsCRFPredictive validityPsychiatrySystematic reviews

Identifiers

PMID31273690
PMCPMC6895673

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.